Navigation Links
The Hemostemix Group of Companies Provides Corporate Strategy Update
Date:5/31/2013

Toronto, Ontario (PRWEB) May 31, 2013

The Hemostemix Group of Companies released an update today available to shareholders and potential investors outlining key elements of its strategic plan for the upcoming year.

The Hemostemix Group is comprised of HemoStemix Ltd. (HemoStemix), a company incorporated in Israel with an operating research, development and manufacturing facility in Ness Ziona, Kwalata Trading Ltd. (“Kwalata”), registered in Cyprus, and the parent company Theravitae, Inc. (“TVI”) based in Toronto, Ontario, Canada (collectively the “Hemostemix Group” or “Group”).

Corporate

On May 14, Technical Ventures RX Corp. (TSX-V:TIK.P) announced a letter of intent signed with TVI regarding a proposed Qualifying Transaction in which TIK.P would acquire TVI in a share exchange. For a copy of the press release, see http://bit.ly/TVI-TIK.

Financing

TVI has also announced that it has engaged Wolverton Securities Ltd. as agent for a private placement, on a commercially reasonable efforts basis, for minimum gross proceeds of $1 million.

Funding

The Hemostemix Group has identified several sources of non-dilutive grant or match funding that it intends to pursue in the near-term for projects which are critical to expediting the company’s commercialization strategy.

Clinical Trial

The Group has completed three clinical trials to-date, the data from which were submitted last year to Health Canada and which formed the basis for its recent clearance to proceed with a phase 2 clinical trial in Canada for the treatment of critical limb ischemia. That trial is expected to start later this year.

Research & Development

Recently the Group also announced that a Lett
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
2. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
3. Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group
4. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5. MZ Group to Sponsor Asia BiotechInvest 2013 Conference
6. DTx Partners with Caxiam Group for DTx.com Redesign
7. Jackson Hole Group, LLC Welcomes Marnie McBryde as a New Principal
8. PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy
9. Cellular Biomedicine Group Provides Update and 2013 Milestones
10. Oncotest GmbH and Debiopharm Group Announce a Successful Partnership in the Identification of Biomarker Candidates
11. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Press attending the Project LIBERTY ... advantage of the people and events in Emmetsburg on ... available throughout the day. Additionally, we will do our ... DSM representatives as well as representatives from the local ... , Please remember to RSVP to Matt Merritt ...
(Date:9/2/2014)... Opertech Bio, Inc., a company ... effective approach to sensory evaluation, today announced the ... U.S. Patent and Trademark Office, encompassing high-throughput sensory ... “Opertech’s taste evaluation technology called Microtiter Operant Gustometer ... system for rapid characterization of taste sensory properties,” ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... $2.1 million. The orders consist of three large odour control ... . "These orders are consistent with the ... Peter Bruijns , President and CEO. "After a difficult ... we are now beginning to see sales growth. Our lower ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... is available in its catalogue: India ... 2019 http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html ... corporations are the main governing bodies responsible for ... in cities. On an average, around 135,000 MT ...
Breaking Biology Technology:Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... ... Delay, LEXINGTON, Mass., ... Glenn L. Cooper,MD, its chairman and chief executive officer is postponing his,previously-announced ... of the recent delay in the approval of NEBIDO(R)., Dr. Cooper ...
... Raymond J. De,Hont, Chairman and Chief Executive Officer ... Fybroc business unit has received,an order for approximately $500,000 ... second and third quarters of the Company,s current fiscal ... order Fybroc has received this year from the,Eastern European ...
... Cell Therapeutics, Inc.,(Nasdaq and MTA: CTIC) today announced that ... million, newly issued 15% Convertible,Senior Notes due 2011, with ... warrant to purchase approximately 14.6 million shares of common ... This transaction constitutes a partial exercise of a previously ...
Cached Biology Technology:Indevus Announces Management Changes 2Indevus Announces Management Changes 3Indevus Announces Management Changes 4Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 2Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 3Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 2
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... study published in the September issue of ... a novel strategy to diagnose the leading cause ... structural damage has occurred. This advance involves quantifying ... the endothelium of retinal vessels. Using new probes ... the early molecular development of diabetic retinopathy. , ...
(Date:9/2/2014)... Best-selling author Sam Kean stops by Reactions this ... 50-foot super shark that, despite what "Shark Week" may ... about it at http://youtu.be/KhFygIoW_MA . , Kean,s book, ... Love and the History of the World from the ... treatment in a 10-episode video series produced for the ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... optogenetics, the researchers are able to target one cell ... to find out exactly what goes wrong in the ... Prof. Dr. Stefan Herlitze (RUB Department for Biology and ... Biological Chemistry . The Bochum team examined a specific ...
... MD FASEB MARC (Minority Access to Research Careers) ... 2011 Society for Leukocyte Biology (SLB) Meeting in Kansas ... are meant to promote the entry of underrepresented minority ... basic science community and to encourage the participation of ...
... - Researchers speaking on the final day of the 6th ... 2011) have focused on the growing interest in the scientific ... have been growing over the past 12 months and are ... Society (IAS) convened working group concentrating its initial efforts on ...
Cached Biology News:Controlling movements with light 2 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 2 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 3 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 4
... development to targets including proteins and to ... cancer-specific surface antigens. A&Gs service is ... in approximately 40 days (duration may vary ... Phase I: Immunization, test bleed and ...
... Immunogen: Synthetic peptide derived from an ... protein. Specificity: Specific for the ... WNT2B/WNT13 proteins. Recognizes both human WNT13A ... Human Rat (positive controls: mouse WNT2B/WNT13-pCMV-tag2-transfected ...
... Clone/PAD: ZMD.460. Immunogen: Synthetic ... the human C35 protein (chromosome 17 open ... Specificity: Specific for the C35 protein. ... band at ~15 kDa band. Reactivity: ...
...
Biology Products: